Stockscreener 앱 받기
59.54
6.16%
-3.91
시간 외 거래:
59.54
전일 마감가:
$63.45
열려 있는:
$62.82
하루 거래량:
2.89M
Relative Volume:
1.42
시가총액:
$9.32B
수익:
$1.22B
순이익/손실:
$77.95M
주가수익비율:
121.71
EPS:
0.4892
순현금흐름:
$224.06M
1주 성능:
-9.60%
1개월 성능:
-10.55%
6개월 성능:
+12.70%
1년 성능:
-11.71%
1일 변동 폭
$58.04
$63.45
1주일 범위
$58.04
$67.60
52주 변동 폭
$46.01
$72.16
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
612-379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
59.54 | 9.93B | 1.22B | 77.95M | 224.06M | 0.4892 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-07-09 | 개시 | TD Cowen | Buy |
| 2025-05-30 | 개시 | Wells Fargo | Overweight |
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
(TECH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call - Finviz
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings - Yahoo Finance
What Are Wall Street Analysts' Target Price for Bio-Techne Stock? - inkl
Bio-Techne Announces Changes to its Leadership Team - Investing News Network
Ex-Dividend Reminder: Bio-Techne, 3M and Eli Lilly - Nasdaq
Madison Asset Management LLC Acquires Shares of 744,651 Bio-Techne Corp $TECH - MarketBeat
Bio-Techne (NASDAQ:TECH) Stock Rating Upgraded by Zacks Research - MarketBeat
Bio-Techne Corp (NASDAQ:TECH) Passes Key Quality Investing Screen - ChartMill
Baader Bank Aktiengesellschaft Buys 38,082 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne: How Spatial Biology Innovation Is Powering a Strategic Comeback! - Smartkarma
Azzad Asset Management Inc. ADV Has $774,000 Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
How Flat Sales, Higher EPS, and New Organoid Tools At Bio-Techne (TECH) Have Changed Its Investment Story - Yahoo Finance
Bio-Techne stock price target raised to $65 from $60 at Stifel By Investing.com - Investing.com Nigeria
New York State Common Retirement Fund Sells 465,634 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne stock price target raised to $65 from $60 at Stifel - Investing.com UK
Wells Fargo & Company Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price - MarketBeat
TECH Stock Update: Wells Fargo Raises Price Target for Bio-Techne | TECH Stock News - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Cor - GuruFocus
Bio-Techne (TECH) Sees Target Price Raised by Stifel | TECH Stoc - GuruFocus
UBS Maintains Buy Rating on Bio-Techne (TECH) with Raised Price Target | TECH Stock News - GuruFocus
Citigroup Raises Price Target for Bio-Techne (TECH) to $80.00 | - GuruFocus
7 Analysts Assess Bio-Techne: What You Need To Know - Benzinga
Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New Research Product Launches - simplywall.st
Tech Stock Update: Evercore ISI Group Raises Price Target for TE - GuruFocus
TD Cowen Maintains Buy Rating on Bio-Techne (TECH) and Raises Pr - GuruFocus
Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $75, Maintains Outperform Rating - marketscreener.com
Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript - Insider Monkey
Techne Corp. (TECH) Q2 Earnings Report: Results Top Analyst ForecastsNews and Statistics - IndexBox
TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets - Finviz
Trading Recap: Is Bio Techne Corporation showing insider buying2025 Analyst Calls & Advanced Technical Signal Analysis - baoquankhu1.vn
Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales - The Globe and Mail
Bio-Techne Corp Plans Quarterly Dividend of $0.08 (NASDAQ:TECH) - MarketBeat
Bio-Techne Releases Second Quarter Fiscal 2026 Results - Investing News Network
Bio-Techne Corp (TECH) Q2 2026 Earnings Call Highlights: Strateg - GuruFocus
Bio-Techne (NASDAQ:TECH) Shares Up 7% on Strong Earnings - MarketBeat
Earnings call transcript: Bio-Techne beats Q2 2026 EPS and revenue forecasts - Investing.com Nigeria
Biotech firm Bio-Techne beats quarterly estimates on strength in key unit - marketscreener.com
Bio-Techne (TECH) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bio-Techne Q2 2026 Earnings Call Transcript - MarketBeat
Bio-Techne (NASDAQ:TECH) Announces Quarterly Earnings Results - MarketBeat
Bio-techne announces $0.08 quarterly dividend payment By Investing.com - Investing.com South Africa
TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up - Yahoo Finance
Bio-Techne Corp announces dividend of $0.08 per share for Q4 2025 - marketscreener.com
Bio-Techne Fiscal Q2 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Bio-Techne (TECH) Surpasses Q2 Revenue Expectations - GuruFocus
Insights into Bio-Techne Q2 Earnings - Benzinga
Bio-Techne Corp (NASDAQ:TECH) Reports Q2 Earnings Beat, Meets Revenue Forecasts - ChartMill
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026 - marketscreener.com
Bio-Techne Earnings Review: Q2 Summary - Benzinga
Earnings Breakdown: Bio-Techne Q2 - Benzinga
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오-테크네 주식 (TECH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McManus Matthew | President - Diag & Spatial Bio |
Feb 01 '26 |
Option Exercise |
0.00 |
4,621 |
0 |
9,356 |
| Hippel James | CFO |
Nov 03 '25 |
Option Exercise |
0.00 |
24,704 |
0 |
154,587 |
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Nov 03 '25 |
Option Exercise |
0.00 |
9,911 |
0 |
25,023 |
| Nusse Roeland | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,599 |
| Nusse Roeland | Director |
Aug 25 '25 |
Sale |
56.36 |
17,040 |
960,388 |
44,559 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,903 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Sale |
56.21 |
17,040 |
957,818 |
44,863 |
1.24%
0.19%
자본화:
|
볼륨(24시간):